DIABETES, AT CLOSE TO 91 MILLION CASES, ACCOUNTS FOR 25% OF ALL NCDS IN INDIA
Future Medicine India|December 2021
The disease incidence, which increases very rapidly in individuals above 35 years of age, accounts for 12.8 million DALYs, 6.7 million YLDs
DIABETES, AT CLOSE TO 91 MILLION CASES, ACCOUNTS FOR 25% OF ALL NCDS IN INDIA

The prevalence of diabetes in India more than doubled in the 16 years since 2005. The number of cases increased from 42.6 mn in 2005 to 85.4 mn in 2019 as per the latest available data. The disease incidence, which increases rapidly in individuals above 35 years, rose at a rate of around 3 million cases per year on average.

Findings of a National Level Survey conducted by The Associated Chambers of Commerce and Industry of India (ASSOCHAM) on the state of diabetes in India revealed that the disease currently accounts for 12.8 million DALYs (Disability-Adjusted Life Years), 6.7 million YLDs (Years Lived with Disability) and 0.3 million deaths during 20052019.

Globally, on the other hand, the prevalence of diabetes increased from 273.4 cases in 2005 to 460 million cases in 2019. Small wonder then that India has the dubious distinction of becoming the global hub for diabetes cases with prevalence increasing from 15.6 percent to 18.6 percent cases in the same interval. Globally, diabetes accounts for 70.9 million DALYs (Disability-Adjusted Life Years) and 36.7 YLDs (Years Lived with Disability) in 2019.

Similar results were found in another prevalence survey conducted by a team of researchers from Vivekananda Yoga Anusandhana Samsthana, Bengaluru, Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, Neuroscience Research Lab at Postgraduate Institute of Medical Education and Research, Chandigarh, College of Social Work at University of Kentucky, US, and Government Medical College and Hospital, Chandigarh, reported in December, 2020. The survey found that India has a high, medium and low diabetes risk score (IDRS) of 10.2 percent, 33.1 percent and 56.7 percent in young adults. The IDRS considers four key factors, including age, family history of diabetes, waist circumference and physical activity.

この蚘事は Future Medicine India の December 2021 版に掲茉されおいたす。

7 日間の Magzter GOLD 無料トラむアルを開始しお、䜕千もの厳遞されたプレミアム ストヌリヌ、8,500 以䞊の雑誌や新聞にアクセスしおください。

この蚘事は Future Medicine India の December 2021 版に掲茉されおいたす。

7 日間の Magzter GOLD 無料トラむアルを開始しお、䜕千もの厳遞されたプレミアム ストヌリヌ、8,500 以䞊の雑誌や新聞にアクセスしおください。

FUTURE MEDICINE INDIAのその他の蚘事すべお衚瀺
VACCINES IN YOUR POCKET
Future Medicine India

VACCINES IN YOUR POCKET

DR. SAUMYA SWAMINATHAN Cheif Scientist, World Health Organisation

time-read
1 min  |
December 2021
DIABETES, AT CLOSE TO 91 MILLION CASES, ACCOUNTS FOR 25% OF ALL NCDS IN INDIA
Future Medicine India

DIABETES, AT CLOSE TO 91 MILLION CASES, ACCOUNTS FOR 25% OF ALL NCDS IN INDIA

The disease incidence, which increases very rapidly in individuals above 35 years of age, accounts for 12.8 million DALYs, 6.7 million YLDs

time-read
4 分  |
December 2021
EXPERTS PREDICT THIRD WAVE IN INDIA WITH MORE THAN A LAKH DAILY CASES IN FEBRUARY
Future Medicine India

EXPERTS PREDICT THIRD WAVE IN INDIA WITH MORE THAN A LAKH DAILY CASES IN FEBRUARY

The active cases have come down as compared July leveld, the threat of new variants is looming large.

time-read
1 min  |
December 2021
END INEQUALITIES TO MEET THE TARGET OF ENDING AIDS
Future Medicine India

END INEQUALITIES TO MEET THE TARGET OF ENDING AIDS

Forty years after the first AIDS case was reported, and 35 years since the first case in India, HIV still threatens us. Today, the world is off track from delivering on the shared commitment to end AIDS by 2030.

time-read
4 分  |
December 2021
UK approves sotrovimab as new covid treatment for high risk adults
Future Medicine India

UK approves sotrovimab as new covid treatment for high risk adults

The Medicines and Healthcare Products Regulatory Agency (MHRA), the drug regulator of the UK, has approved sotrovimab, branded as Xevudy, a new biological drug to fight Covid-19. The drug was found effective to reduce the likelihood of hospital admission and death by about 79 percent in high-risk adults.

time-read
3 分  |
December 2021
Critical Use Of Tractography In Removal Of Brain Tumours
Future Medicine India

Critical Use Of Tractography In Removal Of Brain Tumours

Among Indian surgeons, it is rare to find the skilful art of using Diffusion Tensor Imaging-Fiber Tractography (DTI-FT), a novel MRI technique, to locate the facial nerve on the surface of the brain tumour before surgery

time-read
4 分  |
November 2021
DIGITAL THERAPEUTICS: CHANGING PARADIGMS IN DIABETES CARE
Future Medicine India

DIGITAL THERAPEUTICS: CHANGING PARADIGMS IN DIABETES CARE

With the emergence of DTx programs, doctors and healthcare staffcan extend their care and monitor a patient remotely for faster recovery

time-read
3 分  |
November 2021
ROLE OF NUTRACEUTICALS IN MODERN HEALTHCARE
Future Medicine India

ROLE OF NUTRACEUTICALS IN MODERN HEALTHCARE

With the pandemic teaching us the importance of overall nutrition, people are getting more flexible toward nutraceuticals

time-read
5 分  |
November 2021
Liposomal Nanotechnology and its role in vaccine delivery systems
Future Medicine India

Liposomal Nanotechnology and its role in vaccine delivery systems

In the recent past, there have been many projects to develop sub-unit vaccines that are more effective and defined

time-read
3 分  |
October 2021
CIDRAP RELEASES INFLUENZA VACCINES R&D ROADMAP TO IMPROVE FLU VACCINES
Future Medicine India

CIDRAP RELEASES INFLUENZA VACCINES R&D ROADMAP TO IMPROVE FLU VACCINES

The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota, has released an Influenza Vaccines Research and Development Roadmap (IVR) to accelerate the development of improved seasonal influenza vaccines and the generation of broadly protective or universal influenza vaccines that could mitigate the impact of future influenza pandemics.

time-read
6 分  |
October 2021